logo
Spin scooters might leave D.C. amidst legal battle

Spin scooters might leave D.C. amidst legal battle

Washington Post26-04-2025

A legal fight is heating up between the District and a company that provides e-scooters and bikes in Washington.
Spin, which has over 4,000 bikes and scooters across the District, has been operating in the city since 2019. The District limits the number and type of scooters in the city to avoid crowding sidewalks and streets and D.C.'s vendors are required to apply regularly for permits for the rental bikes and scooters. Those decisions are made by a District evaluation committee that scores the vendors on a 'point-based scoring system' and certain criteria, such as 'equity and affordability,' 'safety,' and 'innovation,' legal documents show.
Despite earning high marks in on previous permit applications, Spin scored third last year, prompting D.C.'s Department of Transportation (DDOT) to award the permit to other companies, including Lime and Veo.
In a lawsuit against DDOT, Spin alleges that the agency gave a European-based competitor, Hopp by Bolt, 'preferential treatment.'
'It is a requirement that agencies stick to their own guidelines,' said Spin's attorney, Michael Klebanov of Husch Blackwell LLP. 'This is really about how DDOT operates and whether their decision making process is being done lawfully.' Spin did not name Hopp by Bolt as one of the parties in its lawsuit.
DDOT initially had a deadline of Friday for removing Spin's bikes and scooters from the District, but it reached an agreement with Spin to allow it to operate for another 30 days while it appeals the process, according to Klebanov.
Companies are required to meet certain deadlines for their applications to operate in the city, including a Nov. 4 deadline for an in-person demonstration to city officials, according to Klebanov. It alleges that Hop was given an extension on the deadline, while Spin and others were forced to adhere to them.
DDOT did not immediately respond to a request for comment. In legal filings, the agency denied Spin's allegations.
In this week's ruling denying Spin's request for a preliminary injunction, U.S. District Judge Jia M. Cobb ruled that 'D.C. statute and regulations give the DDOT discretion to pick new permit holders based on its assessment of each applicant's performance on a set of criteria.' Cobb said that there was no evidence the demonstration was a factor in Spin's failure and that Spin did not ask for an extension.'
The judge went on to write that 'Spin has not met its burden to show that the DDOT failed to apply its published scoring criteria.'
Hopp by Bolt, which is based in Estonia, launched around 720 scooters in D.C. in January. It is the first company in D.C. to offer scooters priced by distance rather than time; its scooters are also equipped with a cognitive test meant to screen out drunk riders.
'Hopp is committed to operating with the highest level of integrity and in full compliance with all regulations in Washington D.C.,' said Daniel Howell, Hopp's regional PR manager for Western Europe and North America.
'We participated in the recent permitting process with transparency and are confident that the District's decisions were made fairly and based on the merits of each application.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Parcel giant Evri delivers jobs to Bury after agreeing DHL tie-up
Parcel giant Evri delivers jobs to Bury after agreeing DHL tie-up

Yahoo

time22 minutes ago

  • Yahoo

Parcel giant Evri delivers jobs to Bury after agreeing DHL tie-up

Evri is planning to hire 5,000 couriers in a fresh recruitment drive as the parcel giant takes on rivals after entering the business letter market. Many of the jobs will working from the company's base in Bury. The Yorkshire-based firm recently announced it was joining forces with DHL's UK ecommerce arm to form one of the country's biggest delivery firms. It said the new roles would bring its total self-employed courier network to 33,000, its highest number. The roles will be available throughout the UK, with a focus on regions including Plymouth, Bury, Hastings, Dover and Scarborough. READ MORE: The legal age children can be left home alone ahead of summer holidays READ MORE: Exact time to see Strawberry Moon in 'record-breaking' phenomenon seen for first time in decades About 1,000 of the new jobs will be permanent, while the rest are set to be flexible positions to cater to the typically busy summer months and other peak periods for deliveries. Couriers who commit to working five or more days a week, including Saturday and Sunday, are also given the chance to opt in to its revamped "Evri Plus" scheme, which includes paid holiday and automatic enrolment into a pension scheme. Evri, which was previously part of the Hermes parcel group, was bought by US private equity firm Apollo for around £2.7 billion last year. It announced plans last month to merge with rival DHL's UK ecommerce business to create a combined company set to deliver more than one billion parcels and one billion letters each year. The deal means Evri will enter the UK business letter market for the first time, bolstering its competition to Royal Mail. Evri has spent £32 million on improving its customer service offering and has seen an improvement in its ratings over recent years, but has said there is "more to do" to improve with customers continuing to report delivery issues. Chief executive Martijn de Lange said: "We know that service, reliability and quality are critical factors for our clients and consumers, and so by expanding our self-employed network further, we remain focused on delivering in each of those areas." Couriers typically earn about £20.90 an hour on average, according to Evri.

Evri to hire 5,000 more couriers after agreeing DHL tie-up
Evri to hire 5,000 more couriers after agreeing DHL tie-up

Yahoo

time27 minutes ago

  • Yahoo

Evri to hire 5,000 more couriers after agreeing DHL tie-up

Evri is planning to hire 5,000 couriers in a fresh recruitment drive as the parcel giant takes on rivals after entering the business letter market. The Yorkshire-based firm recently announced it was joining forces with DHL's UK ecommerce arm to form one of the country's biggest delivery firms. It said the new roles would bring its total self-employed courier network to 33,000, its highest number. The roles will be available throughout the UK, with a focus on regions including Plymouth, Bury, Hastings, Dover and Scarborough. About 1,000 of the new jobs will be permanent, while the rest are set to be flexible positions to cater to the typically busy summer months and other peak periods for deliveries. Couriers who commit to working five or more days a week, including Saturday and Sunday, are also given the chance to opt in to its revamped 'Evri Plus' scheme, which includes paid holiday and automatic enrolment into a pension scheme. Evri, which was previously part of the Hermes parcel group, was bought by US private equity firm Apollo for around £2.7 billion last year. It announced plans last month to merge with rival DHL's UK ecommerce business to create a combined company set to deliver more than one billion parcels and one billion letters each year. The deal means Evri will enter the UK business letter market for the first time, bolstering its competition to Royal Mail. Evri has spent £32 million on improving its customer service offering and has seen an improvement in its ratings over recent years, but has said there is 'more to do' to improve with customers continuing to report delivery issues. Chief executive Martijn de Lange said: 'We know that service, reliability and quality are critical factors for our clients and consumers, and so by expanding our self-employed network further, we remain focused on delivering in each of those areas.' Couriers typically earn about £20.90 an hour on average, according to Evri.

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Yahoo

time33 minutes ago

  • Yahoo

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store